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Integrin 71 is the major laminin binding integrin receptor
ofmuscle cells. The7 chain occurs in several splice isoforms, of
which 7A and 7B differ in their intracellular domains only.
The fact that the expression of 7A and 7B is tightly regulated
during skeletal muscle development suggests different and dis-
tinct roles for both isoforms. However, so far, functional prop-
erties and interacting proteins were described for the7B chain
only. Using a yeast two-hybrid screen, we have found that Def-6,
a guanine nucleotide exchange factor for Rac1, binds to the
intracellular domain of the 7A subunit. The specificity of the
Def-6-7A interaction has been shown by direct yeast two-hy-
brid binding assays and coprecipitation experiments. This is the
first description of an 7A-specific and -exclusive interaction,
becauseDef-6 did not bind to any other tested integrin cytoplas-
micdomain. Interestingly, the bindingofDef-6 to7Awas abol-
ished, when cells were cotransfected with an Src-related kinase,
which is known to phosphorylate Def-6 and stimulate its
exchange activity. We found expression of Def-6 was not only
restricted to T-lymphocytes as described thus far but in a more
widespreadmanner, including different muscle tissues. In cells,
Def-6 is seen in newly forming cell protrusions and focal adhe-
sions, and its localization partially overlaps with the 7A inte-
grin receptor. C2C12 myoblasts overexpressing Def-6 show a
delay of Rac1 inactivation during myogenic differentiation and
abnormal myotube formation. Thus, our data suggest a role for
Def-6 in the fine regulation of Rac1 during myogenesis with the
integrin 7A chain guiding this regulation in a spatio-temporal
manner.
Integrins are heterodimeric cell surface receptors that
bind to components of the surrounding extracellular matrix
(ECM)3 or to other cell surface molecules. They are composed
of two non-covalently linked transmembrane polypeptides (-
and -chain). So far 18 - and 8 -chains have been described,
which form at least 24 integrin receptors with different sub-
strate-binding specificities determined by the individual com-
bination of - and -chains. Besides forming a mechanical link
between the ECM and the cytoskeleton, integrins regulate a
broad variety of signaling events that influence cellular func-
tions such as proliferation, cell differentiation, and apoptosis
(1). Consequently, the cytoplasmic domains of integrin recep-
tors play key roles in the transduction of “outside-in” as well as
“inside-out” signals (2–6). They have been found to interact
with an array of proteins that are part of signaling cascades or
that provide linkage to the actin cytoskeleton (7).
Integrin 71 is mainly expressed in muscle tissues (8, 9),
and the receptor exclusively binds to laminins (10).Muscle pre-
cursor cells (myoblasts) use the 71 receptor to adhere to and
migrate on laminin (11), and laminin-containing ECM
increases the differentiation potential of myoblasts (12). The
importance of this kind of cell-matrix linkage in muscles
becomes obvious when one considers the phenotypes of mouse
null mutants, which lack either the major laminin isoform in
muscles (laminin 2 chain as part of laminin-211)4 (13) or the
integrin 7 chain (14). In both cases, the animals suffer from
severe postnatal muscular dystrophy and muscle wasting.
The integrin 7 chain exists in different splice isoforms (8,
15, 16). The 7X1 and 7X2 splice variants differ in the extra-
cellular putative -propeller domain, a region between the
homology repeats III and IV (17). This leads to different binding
abilities of the receptor for certain laminin isoforms (10). How-
ever, the physiological relevance of these diverse binding affin-
ities is not known.
The splice isoforms 7A and 7B have different amino acid
sequenceswithin the intracellular tail. Interestingly, the expres-
sion of 7A and 7B during muscle development and regener-
ation is tightly regulated, and this regulation pattern is highly
conserved among different mammalian species (15, 18, 19).
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Undifferentiated myoblasts express the 7B splice isoform
only, whereas7A expression is up-regulated after induction of
myotube formation (15). Interestingly, 7 splice variants are
also regulated during muscle regeneration after injury (20).
All these observations strongly suggest an important func-
tion for the 7A chain during differentiation of myoblasts
into myotubes. The cytoplasmic tail of the 7 chain does not
influence the attachment ability of 71 expressing cells to
laminin (21). Therefore the physiological relevance of the dif-
ferent intracellular parts is most likely due to different abilities
of 7A and 7B to interact with intracellular proteins. Thus
theymight function in alternative signaling events duringmus-
cle differentiation and regeneration or provide additional
mechanical linkage to the cytoskeleton.
Rho GTPases are molecular switches regulating a variety of
cellular processes, like endocytosis, cell-cycle progression, dif-
ferentiation, and gene transcription (22). Members of the Rho
GTPase family cycle between an activated GTP-bound state
and an inactivated form in which the GTP has been hydrolyzed
to GDP. Guanine nucleotide exchange factors (GEFs) promote
the exchange ofGDP forGTP, thereby activating RhoGTPases.
Rho GTPases were shown to be strongly involved in the
proper differentiation of myoblasts (23). Specifically, the tight
regulation of Rac1 seems to be important for myogenesis. Dur-
ing normal differentiation of myoblasts the overall endogenous
pool of active Rac1 significantly decreases. However, Rac1
activity is never shut off completely but remains at a basal level
during differentiation (24). In fact, some steps of myogenesis
seem to require locally restricted Rac1 activity (25). The mech-
anisms regulating these complex patterns of Rac1 activity dur-
ing myogenesis are still poorly understood.
In the present study, we report a novel interaction between
the cytoplasmic tail of the integrin 7A chain and Def-6 (also
known as: IBP, SLAT). The Def-6-related protein Swap-70 also
binds to the 7A cytoplasmic domain, albeit with a lower affin-
ity. Def-6 and Swap-70were recently described as a novel group
of GEFs for Rho GTPases (26, 27). Their interactions with 7A
are highly specific and exclusive, because no other integrin
cytoplasmic domain showed binding to these proteins. Inter-
estingly, we found that tyrosine phosphorylation of Def-6 abol-
ishes this interaction. Our data implicate Def-6 in the tight reg-
ulation of Rac1 activity during myoblast differentiation.
EXPERIMENTAL PROCEDURES
DNA Vectors—All yeast two-hybrid pAS2-1 (Clontech) deri-
vate constructs coding for fusion proteins of the GAL4-DNA
binding domain and full-length or truncated intracellular parts
of integrin subunits have been described elsewhere (28). cDNA
fragments encoding the complete sequences of Def-6 (NCBI
accession number gi:142375804) and Swap-70 (NCBI
gi:40789274) or their deletion mutants were generated by RT-
PCR from murine spleen RNA. The RT-PCR fragments were
subsequently cloned in-frame into pACT2 vector (Clontech).
pEBG-derived expression constructs containing GST-7A
orGST-7B and their deletionmutants for expression inmam-
malian cells have been described previously (28). To express
Def-6 in mammalian cells, the Def-6 cDNA insert was sub-
cloned from the pACT2 vector into pEF1-Myc/his (Invitrogen),
pCS2MT (29), or pBabe-neo (30). pBabe-puro constructs
containing the cDNA for the complete 7A or 7B chain have
been already described elsewhere (28).
To generate pBabe-neo/-puro-derived retroviruses, GPE86-
cells (31) were stably transfected with FuGene6 (Roche Applied
Science). Supernatants fromthesecellswerecollectedandused for
the infection of C2C12 cells. 48 h later, selection of infected cells
was started with 1mg/ml G418 or 4 g/ml puromycin.
Yeast Two-hybrid Analysis—The initial yeast two-hybrid
screen to identify novel intracellular binding partners of the
7A1 integrin receptor has been described elsewhere (28).
Briefly, a human placenta cDNA library (MATCHMAKERTM,
Clontech) was screened for proteins that interact with the cyto-
plasmic part of the 7A integrin chain. The intracellular part of
themurine integrin 7A subunit (amino acids 1104–1161) was
cloned in the pAS2-1 vector and used as bait (amino acids posi-
tions refer to NCBI accession code gi:3378242).
For direct yeast two-hybrid analysis, the yeast strain Y190
was cotransformed with the pAS2-1 plasmid containing the
GAL4-DNA binding domain (DBD) fused with appropriate
cDNAs as bait and with pACT2 plasmid containing cDNAs
fused to GAL4-activation domain (AD) as prey. Transformants
were grown on synthetic definedmedium lacking leucine, tryp-
tophan, and histidine in the presence of 25 mM 3-amino-1,2,4-
triazole. On day 6 the colonies were tested for the lacZ reporter
gene activity in a -galactosidase filter assay. The interaction
was scored as negative () when no blue colonies were visible
after 8 h, and scored as: weak (), intermediate (), or strong
() when blue colonies became visible after 8, 4, or 1 h,
respectively. For relative quantification of the -galactosidase
activity, the transformants were first grown on synthetic defined
medium lacking leucine and tryptophan and subsequently intro-
duced into the liquid culture assay using ortho-nitrophenyl--D-
galactopyranoside as substrate. The measured -galactosidase
activitywithin one experimentwas calculated relative to a positive
control, which was set as 100%.
Cell Culture—HEK293, NIH3T3, and HeLa cells were cul-
tured in Dulbecco’s modified Eagle’s medium-high glucose
supplemented with 10% fetal bovine serum. C2C12 myoblasts
were cultured at low densities in growth medium: 1:1 mixture
of Dulbecco’s modified Eagle’s medium-low glucose and F-12/
Ham medium, supplemented with 20% fetal calf serum. To
induce differentiation, growth medium was replaced by differ-
entiation medium (Dulbecco’s modified Eagle’s medium-high
glucose, 2%horse serum).All cells were grown in a 37 °C and 5%
CO2 incubator.
Antibodies—The following antibodies were used: mouse-an-
ti-Myc, clone 9E10 (32), rabbit-anti-GST, and anti-slow skeletal
myosin monoclonal antibody (NOQ7.5.4D, Sigma), mouse-an-
ti-sarcomere myosin (clone MF-20, Developmental Studies
Hybridoma Bank, University of Iowa), mouse-anti-phospho-
tyrosine (clone PY99, Santa Cruz Biotechnology), mouse-anti-
integrin7, clone 3C12 (recognizes the extracellular part of the
receptor) (21, 33), rabbit-anti-integrin 7A (a gift of Ulrike
Mayer, Manchester, UK), mouse anti-Rac1 (BD Biosciences),
peroxidase-conjugated secondary antibodies for immunoblot
analysis (Amersham Biosciences), and secondary fluorescent
antibodies (Dianova and Molecular Probes).
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Polyclonal antibodies against Def-6 were raised against a
bacterially expressed GST fusion protein that contained
amino acids 410–630 of murine Def-6. The final serum was
precleared with GST-loaded glutathione-Sepharose beads
(Amersham Biosciences). Subsequently, Def-6 antibodies
were affinity-purified using GST-Def-6-amino acids 410–630-
conjugated CNBr-Sepharose (Amersham Biosciences). The
specificity of the purified antibodieswas tested by immunoblot-
ting cell lysates from Def-6-transfected cells versus non-trans-
fected cells (Fig. 4C, last two lanes).
Immunofluorescence Staining of Cells—Cells were cultured
on coverslips as indicated in the figure legends. Before staining,
the cells were washed in phosphate-buffered saline, fixed for 15
min with 2% paraformaldehyde at room temperature, perme-
abilized with 0.2% Triton X-100 for 2 min, and subsequently
blocked with 1% bovine serum albumin in phosphate-buffered
saline. The cells were incubated at room temperature for 1 h
with primary antibody and were detected by species-specific
fluorochrome-conjugated secondary antibodies. Fluorescence
images were taken with a Axioplan-2 microscope (Zeiss).
Images shown in Fig. 5 (F and G) were taken with a Zeiss 510
Meta laser-scanning confocal microscope.
Determination of Myotube Fusion Index—C2C12 cells were
grown and differentiated on coverslips. On day 3 after the
switch to differentiation medium, cells were fixed and stained
with 4,6-diamidino-2-phenylindole and anti-sarcomere myo-
sin antibody MF-20. Photos were taken from random fields
(20 objective), and nuclei were counted per field. The fusion
indexwas calculated as the ratio of nuclei in differentiatedmyo-
tubes versus the total amount of nuclei per field.Myotubeswere
defined asMF-20-positive cells, which containmore than three
nuclei. At least four fields were counted per experiment.
Coprecipitation Assays and Immunoblotting—2  105
HEK293 cells were plated in 6-well dishes 48 h before transfec-
tion with FuGene6 transfection reagent (Roche Applied Sci-
ence). 1 g of each cDNA plasmid was used per transfection.
The total DNA amount was equalized with appropriate empty
expression vectors. 30 h after transfection the cells werewashed
with phosphate-buffered saline and lysed in IP buffer (25 mM
Tris, pH 7.5, 137 mM NaCl, 2 mM MgCl2, 10% glycerol, 0.5%
Triton X-100, 1 mM sodium vanadate, 5 g/ml leupeptin, 5
g/ml aprotinin) for 10 min. The lysates were cleared by cen-
trifugation at 13,000  g for 10 min at 4 °C. To reduce nonspe-
cific binding of proteins, Sepharose beadswere blockedwith 1%
bovine serum albumin in IP buffer before incubation with cell
lysates. For GST pulldown experiments, the cleared superna-
tants were incubated for 1.5 h at 4 °C with GSH-Sepharose
beads (Amersham Biosciences). For immune precipitations,
ProteinG-Sepharose beads (AmershamBiosciences) were used
instead. The beads were subsequently washed twice with IP
buffer, boiled in sample buffer, and separated on 10% SDS-
PAGE and immunoblotted as indicated. To detect the peroxi-
dase-conjugated secondary antibodies, an ECL detection sys-
tem (Pierce) was used.
For detection of phosphorylated Def-6 protein in cell lysates,
C2C12 cells were lysed in 2 SDS gel sample buffer and boiled
for 5min, to denature all proteins completely. Subsequently the
samples were diluted 20-fold with phospho-IP buffer (150 mM
NaCl, 20 mM Tris, pH 7.6, 1% Triton X-100, 1% sodium deoxy-
cholate, 1 mM sodium vanadate, 5 g/ml leupeptin, 5 g/ml
aprotinin) to a final concentration of 0.1% SDS. Tyrosine-phos-
phorylated proteins were then precipitated using PY-99 anti-
body and Protein G-Sepharose beads. The beads were washed
four times with phospho-IP buffer before being analyzed by
immunoblotting with anti-Def-6 polyclonal antibody.
Rac1 Activity Assay—Activity assays for Rac1 were per-
formed as previously described (34). Briefly, the cells were lysed
in lysis buffer (50 mM Tris, pH 7.6, 150 mM NaCl, 5 mM MgCl2,
1% Triton X-100, 5 g/ml leupeptin, 5 g/ml aprotinin, 1 mM
phenylmethylsulfonyl fluoride). The lysates were cleared by
centrifugation at 13,000 g for 4min at 4 °C. The supernatants
were incubated for 30 min at 4 °C with glutathione-Sepharose
beads previously loaded with 30 g of GST-tagged PBD (Rac1/
cdc42 binding domain of PAK1). Subsequently the beads were
washed four times in lysis buffer, boiled in sample buffer, and
separated by 15% SDS-PAGE followed by immunoblotting.
RT-PCR—For the isolation of total RNA from cells or tis-
sues, TRIzol (Invitrogen) was used. mRNA was isolated from
the total RNA using Oligotex (Qiagen) and reverse tran-
scribed with the First-strand-cDNA synthesis Kit (Roche
Applied Science). For qualitative expression analysis the
High Fidelity PCR System (Roche Applied Science) was used
with the following primers: Def-6, ACCATGGCCCTGCG-
CAAGGAGCTG/TGGTGCTGGATCCAGTTTTTC; Itga7,
CTCTACAGCTTTGATCGTGCAGC/AAACCACTGGA-




Both Def-6 and Swap-70 Bind Specifically to the Cytoplasmic
Part of the Integrin 7A Subunit—To identify novel proteins
that specifically interact with the cytoplasmic part of the 7A
integrin subunit, we performed a yeast two-hybrid screen. A
human placenta cDNA library was screened with the complete
intracellular domain of the 7A chain (amino acids 1104–
1161) as bait. Out of 288 isolated clones, 7 coded for Def-6 and
2 for Swap-70. Both proteins have recently been described as
GEFs for the Rho GTPase Rac1 (26, 27). Def-6 and Swap-70
differ fromall otherGEFs of theDbl family in that the pleckstrin
homology domain is locatedN-terminal to adbl-homology-like
(DHL) domain, which shows a lowhomology to theDHdomain
of other GEFs like Vav and Tiam1 (26, 35).
To test the specificity of the interactions, direct yeast two-
hybrid analyses were carried out. Def-6 and Swap-70 were
expressed in yeast Y190 cells as AD fusion proteins and tested
for interaction with DBD fusions of several different integrin
cytoplasmic domains (Table 1). Interestingly, with the excep-
tion of 7A, none of the 11 tested -integrin subunits showed
binding to either Def-6 or Swap-70. Also 7B, the splice coun-
terpart of 7A chain, did not interact with these GEF proteins.
According to previous reports, the ninemost C-terminal amino
acids of the 7B chain seem to have an inhibitory effect on the
interaction with other proteins (15, 28). But even a deletion
mutant of the 7B cytoplasmic tail, which lacks these nine
amino acids (7Bdel1), did not bind to Def-6 or Swap-70. Fur-
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thermore, the cytoplasmic domains of neither 1A nor 1D
integrin subunits interacted with these GEF proteins. Nonspe-
cific binding of Def-6 and Swap-70 to the DBD alone could be
excluded, because there was no interaction detectable between
the DBD and AD-Def-6 or AD-Swap-70 (Table 1).
To test the relative binding strengths of Def-6 and Swap-70
to the 7A cytoplasmic domain, quantitative yeast two-hybrid
analysis were performed. The known strong interacting protein
pair p53 and SV40 large T-antigen was used as a positive con-
trol and set as 100%. According to the relative -galactosidase
activity, Def-6 bound to 7A about one order of magnitude
stronger compared with that interaction between Swap-70 and
7A (Fig. 1A, Def-6/7A: 232%  43%; Swap-70/7A: 13.8% 
3.6%). Again, no interaction was detected between Def-6 or
Swap-70 and the DBD protein alone.
Next we tested if these interactions could occur in mamma-
lian cells. HEK293 cells were cotransfected with plasmids cod-
ing for the expression of GST-tagged 7A- or 7B-cytoplasmic
tails and Myc-tagged Def-6 or Swap-70. GST-tagged
7-cytodomains were precipitated and analyzed by immuno-
blotting for the coprecipitation ofMyc-Def-6 orMyc-Swap-70.
Def-6 coprecipitated only with GST-7A, but not with GST-
7Bdel1 or GST alone (Fig. 1B, top panel). Myc-Swap-70
showed the same coprecipitation behavior, except that the
degree of binding to GST-7A was much lower (Fig. 1B, long
exposure blot). Thus the results from coprecipitation experi-
ments correlate well with those obtained by the quantitative
yeast two-hybrid data.
Taken together, these studies show that Def-6 and Swap-70
interactwith the cytoplasmic domain of the integrin7A chain,
but not with any other integrin tested, including 7B and 1
chains. As theA splice isoformof the7 integrin subunit occurs
exclusively in differentiating and mature skeletal muscle cells,
these results suggest a muscle specific role for this interaction.
Mapping of the Interaction-mediating Protein Domains and
AminoAcid Sequences—AsbothDef-6 and Swap-70 bind to the
7A integrin chain, it was of interest to test whether they use
identical binding sites on the 7A chain. To study this, a series
of deletionmutants of the7A cytoplasmic domainwas created
and used for direct yeast two-hybrid interaction assays with
Def-6 and Swap-70, respectively. As shown in Fig. 2A both pro-
teins bind to the full-length7A cytoplasmic domain and to the
7Adel1 deletion mutant, which lacks the last 10 C-terminal
amino acids. Deletion of an additional 13 amino acids (7Adel2),
or more, abrogated the binding of Def-6 and Swap-70. These
data indicate that both Def-6 and Swap-70 use the same amino
acid motif of the 7A chain for interaction which is at least 13
amino acids (GTVGWDSSSGRST) in length.
Def-6 and Swap-70 show an identical arrangement of protein
subdomains: an N-terminal EF-hand motif (EF), a central PH
FIGURE 1. Interaction of Def-6 and SWAP70 with the cytoplasmic domain
of the integrin 7A chain. A, yeast Y190 cells were transformed with GAL4-
DBD and GAL4-AD chimeric constructs. Induced -galactosidase activity was
measured using a liquid o-nitrophenyl--D-galactosidase assay. Three differ-
ent yeast transformants were used for each measurement. The control repre-
sents the interaction of p53 with SV40 large T-antigen, which was set as 100%
of induced -galactosidase activity. The asterisks indicate significant differ-
ences to corresponding controls with DBD vector only (p  0.05 according to
the t test). B, HEK293 cells were transiently transfected with cDNA constructs
as indicated. After 40 h, GST proteins were precipitated (P) with glutathione-
conjugated Sepharose beads (GSH) from cell lysates. The coprecipitated pro-
teins were detected by immunoblots (IB) with monoclonal anti-Myc antibody
(upper blot). The same blot was stripped and subsequently redeveloped with
a rabbit anti-GST antibody (middle blot). The lower panel shows the expression
of Myc-Def-6 and Myc-Swap-70 analyzed by immunoblotting of equal
amounts of total cell lysates with anti-Myc monoclonal antibody.
TABLE 1
Specificity of interaction of Def-6 and Swap-70 with cytoplasmic
domains of different integrin chains
Yeast Y190 cells were cotransformed with GAL4-DNA-BD (DBD) and GAL4-AD
(AD) chimeric constructs. The interaction was evaluated using a -galactosidase
filter assay as described under “Experimental Procedures.”
DBD
AD
Def-6 Swap-70 AD vector
1   
2   
IIb   
3A   
3B   
4   
5   
6A   
6B   
7A      
7B   
7Bdel1   
1A   
1D   
DBD vector   
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domain, and aC-terminalDHLdomain (26, 27, 35). So far, none
of these subdomains have been found to bind to integrin recep-
tors. To investigate if one of these subdomains is sufficient for
interaction with 7A or whether the complete protein struc-
ture is required, a series of deletion mutants for both Def-6 and
Swap-70was generated and tested for binding ability to the7A
cytoplasmic domain in direct yeast two-hybrid assays. Interest-
ingly, only full-length Def-6 and Swap-70 interacted with the
7Acytoplasmic domain.No single subdomain or combination
of domains led to an interaction (Fig. 2B).
Taken together, these experiments show that Def-6 and
Swap-70 bind to the same amino acid motif on the 7A cyto-
plasmic domain. Both Def-6 and Swap-70 only interacted as
full-length proteins with the 7A chain, suggesting that the
three-dimensional structure of the proteins influence their
interaction with the 7A cytoplasmic domain. Events that
change the conformation of these proteins might serve to reg-
ulate the interaction between Def-6 or Swap-70 and the 7A
subunit. Because the binding specificity and features of Def-6
and Swap-70 for the integrin 7A chain were exactly the same
withDef-6 bindingmuch stronger to the7A chain (Figs. 1 and
2), we focused our further studies on Def-6 only.
The GEF-activating Phosphorylation of Def-6 Abolishes Its
Binding Capacity to 7A Cytodomain—It was previously
reported that Def-6 exists in two different conformations. Nor-
mally, an intramolecular interaction keeps the protein in a
closed conformation, thereby inhibiting its GEF activity. Phos-
phorylation of the tyrosine residue Y210 by a Src-related kinase
and binding to cell membrane-associated phosphatidyl inositol
3,4,5-trisphosphate relieves the intramolecular interaction and
activates the GEF (26). Our interaction analysis of Def-6
mutants showed that the entire protein structure is needed for
binding to the7A cytodomain. To test whether the conforma-
tional change of Def-6 induced by Y210 phosphorylation influ-
ences the interaction with the 7A intracellular domain, two
Def-6 mutants were generated. The mutant Y210F cannot be
phosphorylated due to the lack of a hydroxyl residue on the
aromatic amino acid. In contrast, the mutant Y210E mimics
phosphorylation due to the negative charge of the glutamate
(phosphomimetic). These mutants were used for quantitative
direct yeast two-hybrid assays. As shown in Fig. 3A, the binding
of 7A to the Def-6-Y210F mutant was comparable to that of
wild-type Def-6 protein (Def-6 wild type: 232%  43%; Y210F:
159%  83%). In contrast, the Def-6-Y210E mutant did not
show any interaction with the7A cytodomain (Y210E: 3.7%
1.0%; AD only: 1.9%  0.2%), suggesting that the phosphoryla-
tion of Def-6 on Y210 abolishes association with the7A chain.
To confirm these observations in a mammalian cell system,
we expressed these mutants or the wild-type Def-6 as Myc-
tagged proteins along with the GST-tagged 7A or GST alone
in HEK293 cells and performed pulldown assays. The presence
of bound Def-6 in the GST precipitates was checked via immu-
noblotting (Fig. 3B). In accordance with the results obtained in
the yeast two-hybrid experiments, only the Def-6 wild-type
FIGURE 2. Determination of the interacting amino acid motifs and protein domains. Yeast Y190 cells were cotransformed with DBD and AD chimeric constructs.
The interaction was evaluated using a -galactosidase filter assay as described under “Experimental Procedures.” Numbers in the figures refers to amino acid positions
in the corresponding protein. A, interaction of different 7A deletion mutants with Def-6 and Swap-70. The gray box indicates the minimal amino acid motif of the 7A
chain for the binding to Def-6 and SWAP70. B, interaction of different deletion mutants of Def-6 and Swap-70 with the intracellular part of the integrin 7A chain.
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protein and the Def-6-Y210F mutant associated with 7A, but
not the phosphomimetic Def-6-Y210E mutant.
We next tested if the tyrosine phosphorylation of the native
Def-6 molecule also abolishes the binding to the 7A cytodo-
main. The Src-related kinase Lck has been shown to phospho-
rylate Def-6 on tyrosine Y210 (26). Hence, cells were trans-
fectedwith plasmids coding forMyc-Def-6, GST-7A, and Lck.
Three different variants of Lckwere used, wild type (Lck), dom-
inant-negative (Lck-K273E), and constitutively active (Lck-
Y505F) (36). As expected, GST-7A could only be precipitated
by Myc-Def-6 from cells that coexpressed dominant negative
Lck-kinase or no Lck-kinase. In contrast, if wild-type Lck or the
constitutive active variant were coexpressed, the amount of
coprecipitated GST-7A was strongly reduced (Fig. 3C).
In summary, the combination of direct yeast two-hybrid and
coprecipitation assays suggests that Y210 phosphorylation of
Def-6 abolishes its binding to the cytoplasmic domain of the
7A integrin chain. These data imply that only the non-active
GEF is able to bind to 7A, because the phosphorylation of
Y210 was previously shown by others to stimulate exchange
activity of Def-6 (26).
Def-6 Expression in Tissues and the C2C12 Cell Line—To
date, Def-6 function has mainly been analyzed in lymphocytes
(26, 37–39), and no consistent data of Def-6 expression in other
tissues or cell types are available. Because the 7A splice iso-
form is expressed exclusively in differentiating myogenic cells
or in terminally differentiated skeletal myotubes (8, 19, 40), it
was of interest to know whether Def-6 is endogenously
expressed in these cell types. To analyze this, RT-PCRs were
performed with mRNA preparations from spleen and skeletal
muscle originating from an adult c57/Bl6 mouse. The spleen
RNA was used as a positive control and resulted in a Def-6
RT-PCR product of the expected size. Interestingly, a clear and
specificDef-6 PCR product was also amplified from the skeletal
musclemRNApreparation (Fig. 4A). In a parallel PCR reaction,
the existence of 7A mRNA was checked with primers, which
amplify both 7A and 7B but result in different PCR frag-
ments of different length. As expected, 7A as well as 7B
FIGURE 3. Influence of phosphorylation of Def-6-Y210 on 7A binding.
A, the interaction capacities of Def-6 point mutations (Def-6-Y210F and
Y210E) with the cytoplasmic domain of the integrin 7A chain were analyzed by
quantitative yeast two-hybrid assays (performed as described in Fig. 1A).
B, HEK293 cells were transiently transfected with cDNA constructs for GST or
GST-7A and Myc-Def-6 or its mutants (Y210F and Y210E) as indicated. GST
proteins were precipitated (P) and coprecipitated proteins were detected in
immunoblots (IB) with anti-Myc antibody (upper blot). The same blot was
stripped and subsequently redeveloped with a rabbit anti-GST antibody
(middle blot). The lower panel shows the expression of Myc-Def-6 (or its
mutants) analyzed by immunoprecipitating (IP) Def-6 from equal amounts of
total cell lysates and immunoblotting with anti-Myc antibody. C, HEK293 cells
were transiently transfected with cDNA constructs for GST-7A, Myc-Def-6
and one of three different forms of Lck: Lck wild type, Lck-K273E (dominant
negative), and Lck-Y505F (constitutive active). Def-6 protein was immunopre-
cipitated and coprecipitated GST-proteins were detected in immunoblots
with polyclonal anti-GST antibody (upper blot). The same blot was stripped
and subsequently redeveloped with anti-Myc antibody (middle blot). The
lower panel shows the expression of GST-7A analyzed by precipitating GST-
proteins from equal amounts of total cell lysates and immunoblotting with
anti-GST antibody. D, C2C12 cultures were harvested as myoblasts and day 4
myotubes. After lysis and denaturing treatment of the lysate, immunoprecipi-
tations were performed. Def-6 was detected when tyrosine-phosphorylated
proteins were precipitated (PY, antibody: PY99) but not when a control anti-
body was used (control, antibody: 9E10). Panels at the bottom show immuno-
blots of total cell lysates (1:500 of input) stained for Def-6 and the myogenic
differentiation marker sarcomere myosin (antibody: MF20).
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chains were found in muscle tissue according to previous
reports (19). 7BmRNAwas also found in spleen tissue, which
probably originates from smooth muscle cells of blood vessels
expressing only this splice variant of the integrin 7 chain (18).
To exclude that the detected Def-6 mRNA originated from
peripheral blood T-cells, which may have been isolated
togetherwithmuscle tissue, RT-PCR analyseswere also applied
onmRNA preparations from amyogenic tissue culture system.
We used the myogenic cell line C2C12, which differentiates
within several days after growth factor depletion to contractile
myotubes (41). Def-6mRNAwas detected in proliferatingmyo-
blasts (Fig. 4B, day 0) as well as in differentiating myotubes
(days 2–5). Sequencing of the RT-PCR products from C2C12
mRNA further confirmed the Def-6 sequence identity of the
PCR product.5 This clearly shows that Def-6 is indeed
expressed inmuscle cell types. Data presented in Fig. 4B further
demonstrate that the expression of Def-6 during muscle differ-
entiation is not regulated, like the expression of the integrin
7A subunit. The undifferentiated C2C12 myoblasts express
the 7B splice isoform only, whereas the 7A chain is up-reg-
ulated after induction of differentiation (Fig. 4B and Ref. 18).
To extend these expression studies to the protein level, a
polyclonal rabbit serum was raised against Def-6 and subse-
quently affinity-purified. The specificity of this serumwas con-
firmed by immunoblotting lysates from HEK293 cells overex-
pressing Def-6 protein (Fig. 4C, last two lanes). Compared with
lysate from non-transfected HEK293 cells, this serum detects a
strong signal at 75 kDa, which corresponds to the molecular
mass of murine Def-6 (37). Lysates of different mouse tissues
were then analyzed by immunoblotting with this antibody (Fig.
4C). As expected, the highest expression of Def-6 protein was
detected in thymus and spleen. Interestingly, Def-6 protein was
also present in all organs tested, including different muscle tis-
sues (heart, tongue, and skeletalmuscle (Fig. 4C)). Additionally,
lysates from differentiating C2C12 cells were analyzed for
Def-6 protein. In accordance to the RT-PCR data, the expres-
sion of Def-6 protein was not changed during the differentia-
tion (Fig. 4D). The proper differentiation of theC2C12 cells was
confirmed by immunoblot analyzes of the same lysates with
antibodies against the muscle-specific marker “slow myosin
heavy chain” and the A splice isoform of the 7 integrin chain.
Taken together, these results demonstrate that Def-6 is endog-
enously expressed in several mouse tissues and cells, including
skeletal muscle and in the myoblast cell line C2C12.
Next we questioned if endogenous Def-6 protein in C2C12
myoblasts is phosphorylated and if this phosphorylation
changes during myogenic differentiation. We performed
immunoprecipitations of tyrosine-phosphorylated proteins
from C2C12 cells. To avoid a potential coprecipitation instead
of a direct precipitation, the immunoprecipitation was per-
formed after a denaturing treatment of the cell lysates. Indeed,
Def-6 was found to be tyrosine-phosphorylated in myoblasts
and myotubes at a low level, because it was detected in the
precipitates by immunoblotting of the precipitates with
polyclonal Def-6 antibody (Fig. 3D). The relative amount of
phosphorylated Def-6 changed little frommyoblasts to myo-
tubes. Specificity of the immunoprecipitation was confirmed
by using the 9E10 antibody as a control, by which Def-6 was
not precipitated.
Def-6 Localizes at Cell Protrusions and Focal Adhesions—To
investigate the subcellular localization of Def-6, different cell
types (NIH-3T3, HeLa, and C2C12) were transfected with
expression constructs for Def-6 and subsequently analyzed by
immunofluorescence microscopy (Fig. 5). The protein was
found to localize to the edge of lamellipodial cell protrusions
(Fig. 5A) and to focal adhesions (Fig. 5B).
Next we wanted to study whether the intracellular localiza-
tion of Def-6 is influenced by the 7A1 integrin receptor in
myogenic cells. We first tried using the polyclonal anti-Def-6
antibody, but this resulted in inconclusive staining of C2C12
myoblasts.5 Despite a well detectable band of endogenous
Def-6 protein in immunoblotting analysis ofC2C12 lysates (Fig.
4D), its expression seemed to be below the level of detection for
immunofluorescence applications. To overcome this problem,
Def-6 protein was stably overexpressed in C2C12 cells (Fig. 5C,
left panel). Because undifferentiated myoblasts express only
integrin 7B1, the 7A subunit was also expressed by a retro-
viral gene transfer in Def-6-overexpressing C2C12 cells. Myo-
blasts infected with retroviruses for 7B expression served as a
control. The expression of the integrin 7A chain was con-
firmed by immunoblotting (Fig. 5C, right panel). These cells
were plated on coverslips precoated with laminin-111, an ECM
substrate for the 71 receptor. The immunofluorescence
analysis of these cells revealed thatDef-6 localizes to focal adhe-
5 T. Samson, C. Will, A. Knoblauch, L. Sharek, K. von der Mark, K. Burridge, and
V. Wixler, unpublished observation.
FIGURE 4. Endogenous expression of Def-6. Mouse tissues and C2C12 cells
were analyzed for expression of Def-6. A and B, different mRNA preparations
were analyzed by RT-PCR. The different primer combinations led to the ampli-
fication of specific PCR fragments of Def-6, 7 integrin chain or glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH). The 7 primers anneal to both
splice variants (7A and 7B), resulting in different lengths of the PCR prod-
uct. The C2C12 cultures were harvested at different times after the switch to
differentiation medium (day 0). C and D, radioimmune precipitation assay
lysates from different mouse tissues and C2C12 cells were analyzed by immu-
noblotting (used antibodies are indicated). HEK293 cells, which overex-
pressed Def-6 protein, were used as a positive control for the anti-Def-6
serum. Dots in C indicate 32, 56, and 88 kDa. 50 g of total protein was loaded
per lane. n.d., not determined.
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sions and lamellipodia, as seen in fibroblasts (NIH-3T3) and
epithelia cells (HeLa). Further, in these structures Def-6 local-
ization partially overlaps with laminin-binding 71 integrin.
The same observations were noted for 7A- and 7B-express-
ing cells (Fig. 5, D and E).
Taken together, these results show that Def-6 localizes to
lamellipodia and focal adhesions. This distribution is independ-
ent of the 7A integrin chain, because it was observed also in
cells that do not express this integrin chain. However, when
7A and Def-6 are present within one cell, they partially colo-
calize in focal adhesions.
To study where Def-6 localizes in C2C12 cells during the
differentiation frommyoblasts to myotubes we used the Def-6-
overexpressing C2C12 cells (Fig. 5C, left panel). The cells were
plated on uncoated coverslips and subsequently induced to dif-
ferentiate. In undifferentiated myoblasts we again detected
Def-6 in cellular protrusions (Fig. 5F). Inmyotubes Def-6 local-
ized to the sarcolemma where a clear colocalization with the
integrin7 chain could be observed (Fig. 5G). It is worth noting
that the analyzed myotubes (day 4 after induction of differenti-
ation) express endogenously the integrin 7A chain.
Def-6 Influences Differentiation of C2C12 Myoblasts—Dur-
ing differentiation of myoblasts expression of the 7A integrin
chain is gradually up-regulated. Because Def-6 binds to the
cytoplasmic tail of 7A, we next tested if myogenic differentia-
tion of theDef-6-overexpressingC2C12 cells is affected. C2C12
cells, which were infected with an empty-vector virus,
expressed only the endogenous level of Def-6 and served as a
control (Fig. 5C, left panel). These cells were plated on 6-well
dishes, and differentiation was induced after 24 h. Progression
of morphological changes in the differentiating cultures were
monitored by microscopy (Fig. 6A). Empty vector-infected
C2C12 cells aligned and fused normally like uninfected cells.
Fusion of control cells started to occur on day 2 after growth
factor deprivation. On day 5 they showed a high density of par-
allel arrays of thin and mainly unbranched myotubes. Def-6-
overexpressing myoblasts also began to fuse on day 2, but in
contrast to empty vector-infected cells they tended to lose con-
tact to the tissue culture dish, which resulted in lower cell den-
sity. In addition, the myotube formation of Def-6-overexpress-
ing cells was severely impaired. A subset of these cells formed
strongly branched and very thick myotubes after 3 days (Fig. 6,
B and C). Nevertheless, the control cells as well as the Def-6-
overexpressing cells underwent myogenic differentiation,
because sarcomericmyosinwas expressed in both cases (MF-20
staining, Fig. 6B). Measuring the thickness of fused myotubes
FIGURE 5. Subcellular localization of Def-6. A and B, different cell types were
transiently transfected with a Def-6 expression construct, plated on cover-
slips, and stained for immunofluorescence. A, NIH-3T3 fibroblast plated on
laminin-111; a, Def-6; b, actin; c, merged image; image d represents a higher mag-
nification of the frame in image c. B, HeLa cell; red, Def-6; green, actin. C, C2C12
myoblasts were stably transduced with an expression construct for Def-6 (left
panel). These Def-6-overexpressing cells were subsequently transduced with
expression constructs for the integrin chain 7A or 7B. Expression of 7A
was verified by immunoblotting (right panel). D and E, cells were plated on
laminin-111-coated coverslips. D, 7A/Def-6-expressing C2C12 cells. E, 7B/
Def-6-expressing C2C12 cells. Cells in D and E were stained for Def-6 (D, panel
a and E, panel a) and the 7 integrin chain (D, panel b and E, panel b). Merged
images are shown in D, panel c and E, panel c. The white arrows indicate
regions of partial colocalization. F and G, Def-6-overexpressing C2C12 cells
were fixed, stained either as myoblasts (F) or as differentiated myotubes (G),
and analyzed using confocal microscopy. Panels: a, Def-6; b, 7 integrin chain;
and c, merged image. The white bars represent 10 m.
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revealed that those originating from Def-6-overexpressing
C2C12 cells had about twice the diameter compared with con-
trol myotubes (Fig. 6C). In addition, differentiated Def-6-over-
expressing C2C12 cultures exhibited an unusually high fusion
index (Def-6-overexpressing cells: fusion index  0.4; control
cells: fusion index 	 0.26; Fig. 6D), and such myotubes had an
increased amount of nuclei (Def-6-overexpressing myotubes:
40 nuclei; control myotubes: 15 nuclei; Fig. 6E). The nuclei
were often accumulated in clusters at branch points of themyo-
tubes (arrows in Fig. 6B).
These results show that Def-6 affects the differentiation and
myotube formation of C2C12 cells. Because Def-6 has been
shown to be an Rac1GEF (26) and because high Rac1 activity in
C2C12 cells impairsmyoblast differentiation (24), wemeasured
Rac1.GTP levels in Def-6-overexpressing cells during differen-
tiation (Fig. 7A).Although the level ofRac1.GTP in controlC2C12
cells decreased soon after the switch to differentiation medium
(starting at day 1), Def-6-overex-
pressing cells delayed this down-
regulation. During days 1–3 of the
differentiation, the Rac1.GTP levels
were elevated compared with con-
trol cells. Only later the Rac1.GTP
level gradually decreased to that of
the control cells. Control immuno-
blots for the myogenic differentia-
tionmarkers sarcomeremyosin and
7A integrin chain confirmed that
both cell lines underwent myogen-
esis (Fig. 7B).
Taken together, these experi-
ments show that overexpression of
Def-6 in C2C12 myoblasts impairs
the down-regulation of Rac1 activ-
ity, causing dysregulated formation
of unusually thick and branched
myotubes.
DISCUSSION
Here we report a specific interac-
tion between the Rac1 GEF Def-6
and the cytoplasmic domain of the
integrin chain 7A, which is a splice
isoform expressed exclusively in
skeletal muscle tissues. This inter-
actionwas found to be inhibited by a
tyrosine phosphorylation of Def-6,
which was described to stimulate
the GEF activity of this protein. Fur-
ther, we show a widespread tissue
distribution of Def-6, including dif-
ferent muscle types and the C2C12
myoblast cell line. The protein
localizes to cellular protrusions and
focal adhesions where it overlaps
with 71 distribution. Overex-
pression of Def-6 in C2C12 myo-
blasts leads to elevated Rac1.GTP
levels and altered myogenic differentiation.
The process of muscle development and regeneration is a
complex cascade of numerous cell functions, which finally lead
to the formation of myofibers. Undifferentiatedmyoblasts pro-
liferate andmigrate on ECM substrates (12, 42), align with each
other, and eventually fuse to formmulticellular myotubes (43).
This process is accompanied by a cell cycle arrest and expres-
sion of muscle-specific genes (44). Both, Rac1 and 71 inte-
grinwere described to affect differentiation andmaintenance of
muscles (9, 23). Because the integrin 7A chain is a splice iso-
form exclusively expressed in skeletal muscle cells andDef-6 is
aGEF for Rac1, this interaction could provide a skeletalmuscle-
specific signaling link between integrin 71 and the Rho
GTPase Rac1.
Integrin 71 was shown to be important for development
and homeostasis of muscles, because mice deficient for the
integrin 7 chain show both a partial embryonic lethality and
FIGURE 6. Def-6 overexpression impairs differentiation of C2C12 myoblasts. A, myogenic differentiation of
C2C12-control or Def-6-overexpressing C2C12 cells was induced by switching the culture medium to differen-
tiation medium (day 0). Phase micrographs of differentiating cells were taken at different times (days 1, 3, and
5). Def-6-overexpressing C2C12 cells formed arrays of unparallel and branched myotubes and cells tended to
detach from the tissue culture dish during differentiation. B, differentiating cultures were fixed on day 3 and
stained with 4,6-diamidino-2-phenylindole and the myogenic differentiation sarcomeric myosin (MF-20). The
arrows indicate clusters of nuclei in myotubes originating from Def-6 overexpressing C2C12 cells. C–E, different
parameters of differentiating C2C12 control cells and two different Def-6-overexpressing clones. Def-6-over-
expressing C2C12 cells developed myotubes with increased average diameter (C) and number of nuclei per
myotube (E). The fusion index of Def-6-overexpressing C2C12 cells was also increased (D). Data in C–E are
mean  S.E.
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muscular dystrophy in adult animals (14). Interestingly, inte-
grin 51 is up-regulated in 7-deficient mice (45); however,
the compensation is obviously incomplete, because severemus-
cle wasting can be observed in these animals. This may be at
least partly due to the fact that 51 is a fibronectin receptor
instead of a laminin receptor. In addition, the intracellular
domains of the 5 and both 7 splice isoforms are different,
which implies diverse intracellular protein interactions and sig-
naling events. So far, all experiments attempting to elucidate
the signaling capacity of the 7 intracellular domain were per-
formed with 7B-expressing cells or in myoblasts where the
exact expression of splice isoforms was not analyzed. Mielenz
and coworkers (21) found that 7B interacts with a p130CAS/
crk complex. The muscle integrin-binding protein was shown
to interact with 7B, thereby regulating laminin matrix depo-
sition and paxillin signaling (46). FHL2 and FHL3 bind to 7A
and 7B, but not to 5 (28), which may be one reason for the
failure of integrin 5 compensation in 7-deficient mice. FHL2
and FHL3 were also found to bind to actin (47), which suggests
that they may link 7A and 7B to the actin cytoskeleton. All
this could be necessary to provide a more stable connection
between integrins and the cytoskeleton, to resist the strong
mechanical forces acting on muscle cells. Interestingly, the
muscle-specific splice variant 1D was also shown to provide a
stronger link to the actin cytoskeleton (48). However, although
FHL2 and FHL3 are the only proteins found to bind to the 7A
cytoplasmic domain, these interactions are not exclusive,
because other integrin cytoplasmic domains (including 7B)
also interact with FHL2 and FHL3 (28, 29). No functional data
about a specific and exclusive role for 7A1 have yet been
obtained, and the question why muscles express 7A and 7B
splice variants has not been answered so far. Likewise, the tissue
distribution and subcellular localization of 7A does not give a
conclusive indication about a specific function. Except for the
finding that the7A splice isoformonly occurs in differentiated
skeletal muscles (19), 7A and 7B always codistribute within
the muscle cell, for example at myotendinous and neuromus-
cular junctions (49). So far, 7A has not been reported to local-
ize exclusively without 7B at any cellular compartment of
muscle cells.
Our studies started with the goal of identifying proteins
that bind specifically to the 7A isoform. The finding that
Def-6 and Swap-70 bind to the intracellular domain of the
7A receptor is the first description of exclusive and specific
interactions with this integrin chain. We were able to con-
firm this interaction by direct yeast two-hybrid assays and
coprecipitation experiments from transfected mammalian
cells. Our interaction studies clearly show an 7A-specific
binding of Def-6, because it did not bind to -chains, which
form integrin receptors for the majority of ECM ligands:
11 and 21 as collagen receptors, 31, 61, and 71
as laminin receptors, and 51 and 41 as fibronectin
receptors. Finally, the interaction specificity for 7A versus
7B was further proven by analyzing a deletion mutant of
7B, which lacks a putative C-terminal inhibitory domain
(15). We have previously shown that this deletion mutant
interacts strongly with FHL2 and FHL3 (28), but here we did
not find binding to Def-6 or Swap-70. Most integrin intra-
cellular binding proteins have been found to interact with 
chains (7). Interestingly, Def-6 and Swap-70 did not show
binding to the 1A isoform or the muscle specific isoform
1D. Within our interaction studies we also tried to copre-
cipitate Def-6 with the 7A chain from cell lysates of C2C12
myotubes, which endogenously expressed both proteins.
However, because interactions between intracellular pro-
FIGURE 7. Elevated Rac1.GTP levels in Def-6-overexpressing C2C12 myo-
blasts during differentiation. A, the amount of Rac1.GTP in differentiating
C2C12 cultures was determined at different times by precipitating Rac1.GTP
from total cell lysates using GST-PBD (left panel) as described under “Experi-
mental Procedures.” The panel on the right shows immunoblotting of equal
amounts of total cell lysates. Compared with empty vector-infected C2C12
cells, Def-6-overexpressing cells had a delayed decrease of Rac1.GTP levels
during differentiation. Only later (days 4 and 5), Def-6-overexpressing cells
also decreased the amount of activated Rac1.GTP. B, immunoblots that show
expression of Def-6, sarcomeric myosin (MF20), and 7A integrin in differen-
tiating C2C12 control and Def-6-overexpressing cells.
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teins and cytoplasmic domains of integrins are often very
weak, these attempts did not lead to conclusive results.5
Def-6 and Swap-70 represent a novel family of Rho-GEFs
that have recently been described (26, 27). The classic
arrangement of DH/PH domains is inverted in these GEFs.
In addition, the degree of homology of the Def-6 and
Swap-70 DH-like domains to other DH domains is not sig-
nificant, and a potential coiled-coil stretch was identified
within this region (50). So far, Def-6 was reported to be
mainly associated with functions of lymphocytes with high-
est expression in T-cells and T-cell homing organs (26, 37,
38). Here we confirmed the high expression of Def-6 in the
thymus as a T-cell compartment (Fig. 4C), but additionally
we detected Def-6 mRNA and protein expression in all
tested organs, including muscle tissues (heart, skeletal mus-
cle, and tongue) and the C2C12 myoblast cell line. After
initial reports that expression of Swap-70 is almost exclu-
sively restricted to B-cells (51), it turned out that this protein
is present in a more widespread manner (52) with a signaling
function upstream of Rac1 (27). Likewise, our RT-PCR anal-
ysis also revealed Swap-70 expression in skeletal muscle tis-
sue.5 Similarly, our expression analysis of Def-6 also showed
a more general distribution, indicating that it functions in
cell types other than T-cells. Mavrakis and coworkers (35)
have already suggested endogenous expression of Def-6 in
NIH-3T3 fibroblasts.
Rac1 activity levels and its downstream signaling effects
during myoblast differentiation are still an active field of
discussion and controversy (23). Overall, Rac1 activity has to
decrease for proper myoblast differentiation, because over-
expression of constitutive active Rac1 in C2C12 myoblasts
leads to impairment of differentiation (24). However, several
steps during myogenesis seem to require Rac1 activity in
certain compartments of the cell. Rac1.GTP is required for
the formation of acetylcholine clusters, and overexpression
of constitutively active Rac1 increases the clustering of ace-
tylcholine receptors on myotubes (25). Expression of mus-
cle-specific genes in the nuclear compartment were shown
to be regulated by Rac1, even though the results are incon-
sistent concerning the mode of regulation (53, 54). In foun-
der cells of forming muscles in Drosophila, Rac1 becomes
specifically aggregated at fusion sites (55). In summary, all
these findings indicate that Rac1 regulates certain locally
restricted steps of differentiation, even though the net Rac1
activity level decreases in differentiating myoblasts.
It is thus interesting that we found an interaction of a Rac1
GEF and a muscle-specific integrin, which is regulated during
myogenesis. Indeed, focal adhesions containing 7A also con-
tained Def-6, even though we observed Def-6 localization to
focal adhesions independently of7A as well. Thus, subcellular
localization of Def-6 must be guided by interactions with other
proteins or binding of the Def-6-PH domain to phosphatidyl-
inositol phosphates. Def-6 membrane localization was previ-
ously shown to be dependent on phosphatidylinositol 3-kinase
activity (35). Because Def-6 does not bind to 7A when it is
tyrosine-phosphorylated, this interaction could provide a
mechanism to recruit inactive Def-6 to certain areas of the cell.
Because7A is up-regulated during differentiation, itmight act
to sequester inactive Def-6, thereby contributing to the general
decrease in Rac1 activity that accompanies myogenesis. Alter-
natively, by recruiting Def-6 to specific sites where this integrin
is concentrated, the association between 7A and Def-6 may
allow local activation of Rac1 at these sites, for example by
phosphorylation of Def-6 by Src family kinases.
Interestingly, the Src family kinase Yes is up-regulated and
activated in differentiating myoblasts (56), and we indeed
detected tyrosine-phosphorylated Def-6 in C2C12 myoblasts
and myotubes. However, the amount of phosphorylated Def-6
was low, and the relative total amount of phosphorylated Def-6
did not change dramatically from myoblasts to myotubes,
implying that Def-6 phosphorylation probably occurs only in a
small area of the cell.
Down-regulation of Rac1was shown to be essential for estab-
lishing the cell cycle exit of differentiatingmyoblasts (24).Over-
expression of constitutive active Rac1 in differentiating myo-
blasts delays the cell cycle exit, and the resulting myotubes are
much thicker. Interestingly, when we overexpressed Def-6 in
C2C12 myoblasts, we observed the same phenotype. The myo-
tubes were much thicker compared with control cells, and the
number of nuclei was increased. The Rac1.GTP level in differ-
entiating C2C12 myoblasts overexpressing Def-6 was initially
higher compared with control cells. By day 5 it decreased to a
level comparable to that found in control cells. This observation
strongly suggests that the GEF activity of Def-6 is normally
down regulated in differentiating myoblasts, because the over-
all Def-6 amount is not changed (Fig. 4D). Due to the high
amount of Def-6 protein in overexpressing cells, this fine regu-
lation is probably delayed, because mechanisms that normally
down-regulate Def-6 GEF activity or the localization of Def-6
are overstrained.
To further analyze the role of Def-6 during myoblast differ-
entiation, we also attempted to generate Def-6 knockdown cell
lines. To date a successful knockdown of Def-6 has not been
reported, andwe did not get a reliable and efficient reduction of
Def-6, despite numerous attempts using different RNA inter-
ference sequences and transfection methods.5 Similar difficul-
ties with knocking down a different GEF (GEFT) in C2C12
myoblasts have been reported (57). Themouse knock-outmod-
els of both Def-6 and Swap-70 genes have been generated (58–
60), but the published reports have focused on lymphocyte-
specific functions only. Whether muscle functions are affected
in these mice has not been reported, and it might be that a mild
muscle phenotype was not yet detected. On the other hand, it is
possible that Def-6 and Swap-70 are functionally redundant,
because both have GEF activity on Rac1, and both can bind to
the same amino acid sequence in the cytoplasmic domain of
7A. Indeed, our PCR analysis also revealed Swap-70 in C2C12
myoblasts.5 Redundancy seems to be a general feature of
GTPase regulators, as it was reported for the Vav GEF family
(61) as well as the GTPase-activating proteins Bcr andAbr (62).
In summary, we have found that Def-6 and Swap-70 bind
to the cytoplasmic part of the 7A integrin chain, which is
the first description of a specific interaction with this inte-
grin splice variant. Our data suggest that Def-6 as a GEF for
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Rac1 has a role during formation of myotubes. Def-6 and its
activity have to be precisely regulated for proper differenti-
ation of myoblasts. The interaction between 7A and Def-6
could serve as a mechanism to locally restrict Def-6 GEF
activity within differentiating cells. We hope to clarify this
question by employing recently developed FRET-based bio-
sensor technologies, which allow measurement of locally
restricted Rac1 activity.
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